You searched for: interferoonravi (Estniska - Engelska)

krooniline staadium, interferoonravi ebaõnnestumine.
chronic phase, interferon failure:

eelnevalt interferoonravi mittesaanud patsiendid täiskasvanud patsiendid:
naïve patients adult patients:

beeta-interferoonravi ajal võib suureneda antikehade moodustumine.
an increased formation of auto-antibodies may occur during treatment with interferon beta.

kuna palavikku saab seostada interferoonravi puhul sageli ette tuleva gripitaolise
while fever may be associated with the flu-like syndrome reported commonly during interferon therapy, other causes of persistent fever must be ruled out.

täiskasvanud patsientidel, kes saavad interferoonravi kombinatsioonis ribaviriiniga, on saavutatud
in adult patients receiving interferon in combination with ribavirin, the achieved sustained response rate is no

kombinatsiooni ribaviriiniga kokku 345 eelneva alfa- interferoonravi kogemusega patsienti.
a total of 345 interferon alpha relapse patients were treated in two clinical trials with t

nefrootilist sündroomi tuleb koheselt ravida, kaaluma peab beeta-interferoonravi katkestamist.
prompt treatment of nephrotic syndrome is required and discontinuation of treatment with betaferon should be considered.

alfa-2b-interferoonravi tuleb taasalustada eelnevast 50% võrra madalama annusega.
interferon alfa-2b treatment is to be restarted at 50 % of the previous dose.

täiskasvanud patsientidel, kes saavad interferoonravi kombinatsioonis ribaviriiniga, on saavutatud püsiv ravivastuse määr 47 %.
in adult patients receiving interferon in combination with ribavirin, the achieved sustained response rate is 47 %.

pe täiskasvanud patsientidel, kes saavad interferoonravi kombinatsioonis ribaviriiniga, on saavutatud püsiv ravivastuse määr 47%.
47%.

345 kroonilise hepatiit c patsienti, kellel interferoonravi järgselt tekkis retsidiiv, said 6 kuud ravi ja olid ravijärgselt 6 kuud jälgimisel.
retreatment of relapse patients with ribavirin and interferon alfa-2b combination treatment two trials examined the use of ribavirin and interferon alfa-2b combination treatment in relapse patients (c95-144 and i95-145); 345 chronic hepatitis patients who had relapsed after previous interferon treatment were treated for six months with a six month follow-up.

introna koosmanustamine ribaviriiniga suurendas introna efektiivsust kroonilise c-hepatiidiga ja varasema interferoonravi kogemusteta patsientidel vähemalt kaks korda.
co-administration of introna with ribavirin increased the efficacy of introna by at least two fold for the treatment of chronic heptatitis c in naïve patients.

345 kroonilise c- hepatiidiga patsienti, kellel interferoonravi järgselt tekkis retsidiiv, said 6 kuud ravi ja olid ravijärgselt 6 kuud jälgimisel.
retreatment of relapse patients with rebetol and interferon alfa-2b combination treatment two trials examined the use of rebetol and interferon alfa-2b combination treatment in relapse patients (c95-144 and i95-145); 345 chronic hepatitis patients who had relapsed after previous interferon treatment were treated for six months with a six month follow-up.

viraferon koosmanustamine ribaviriiniga suurendas viraferon’i efektiivsust kroonilise c-hepatiidiga ja varasema interferoonravi kogemusteta patsientidel vähemalt kaks korda.
co-administration of viraferon with ribavirin increased the efficacy of viraferon by at least two fold for the treatment of chronic heptatitis c in naïve patients.

71 viraferon koosmanustamine ribaviriiniga suurendas viraferon’ i efektiivsust kroonilise c- hepatiidiga ja varasema interferoonravi kogemusteta patsientidel vähemalt kaks korda.
co-administration of viraferon with ribavirin increased the efficacy of viraferon by at least two fold for the

eelneva südamehaiguseta patsiendil on harva kirjeldatud kardiomüopaatiat, mis võib alfa- interferoonravi katkestamisel olla pöörduv (vt lõik 4. 4).
cardiomyopathy, that may be reversible upon discontinuation of interferon alpha, has been reported rarely in patients without prior

interferoonravi saanud kroonilise c-hepatiidiga patsientidel täheldati vogt-koyanagi-harada (vkh) sündroomi juhtude ilmnemist.
cases of vogt-koyanagi-harada (vkh) syndrome have been reported in patients with chronic hepatitis c treated with interferon.

kaasa arvatud patsiendid, kellel eelneva interferoonravi (pegüleeritud või mittepegüleeritud, koos ribaviriiniga või ilma) ajal esines haiguse retsidiiv, osaline või puuduv ravivastus.
includes relapsers, partial and null reponders to prior treatment with interferon (pegylated or non-pegylated), with or without ribavirin.

kroonilise c-hepatiidiga patsientidel, kes said interferoonravi, täheldati vogt-koyanagi-harada (vkh) sündroomi juhtude ilmnemist.
cases of vogt-koyanagi-harada (vkh) syndrome have been reported in patients with chronic hepatitis c treated with interferon.

kroonilise c-hepatiidiga patsientidel, kes said interferoonravi, täheldati vogti-koyanagi-harada (vkh) sündroomi juhtude ilmnemist.
cases of vogt-koyanagi-harada (vkh) syndrome have been reported in patients with chronic hepatitis c treated with interferon.